Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial
Phase II trial shows azacitidine improves progression-free survival in elderly AML patients unable to continue intensive treatment, suggesting a safe maintenance option.
Key Points
Patients exhibited a median overall survival of 11.5 months, indicating the potential effectiveness of azacitidine.
Overall response rates showed complete remission in 46.9% and partial remission in 15.6%, highlighting treatment impact.
This single-arm phase II trial assessed maintenance therapy using azacitidine in patients with acute myeloid leukemia after initial chemotherapy.
Results suggest azacitidine may provide a beneficial maintenance option for elderly AML patients with improved quality of life.